Group 3 innate lymphoid cells: Regulating host-commensal bacteria interactions in inflammation and cancer

International Immunology

Volumn 28, Issue 1, 2016, Pages 43-52

  Goc, Jeremy ^a   Hepworth, Matthew R ^a   Sonnenberg, Gregory F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cancer; Commensal bacteria; Innate lymphoid cells; Intestinal homeostasis

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6;

ADAPTIVE IMMUNITY; ARTICLE; CANCER GROWTH; CARCINOGENESIS; COMMENSAL; CYTOKINE PRODUCTION; HOST PATHOGEN INTERACTION; HUMAN; INFLAMMATION; LYMPHOID CELL; MICROFLORA; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; ANIMAL; HOMEOSTASIS; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; INTESTINE MUCOSA; LYMPHOCYTE; MICROBIOLOGY; SYMBIOSIS;

ANIMALS; CARCINOGENESIS; HOMEOSTASIS; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INFLAMMATION; INTESTINAL MUCOSA; LYMPHOCYTES; NEOPLASMS; SYMBIOSIS;

EID: 84954290481     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxv056     Document Type: Article

References (137)

1. Kotas, M. E. and Medzhitov, R. 2015. Homeostasis, inflammation, and disease susceptibility. Cell 160:816.
2. Hanahan, D. and Weinberg, R. A. 2011. Hallmarks of cancer: the next generation. Cell 144:646.
3. Grivennikov, S. I., Greten, F. R. and Karin, M. 2010. Immunity, inflammation, and cancer. Cell 140:883.
4. Belkaid, Y. and Hand, T. W. 2014. Role of the microbiota in immunity and inflammation. Cell 157:121.
5. Hooper, L. V., Littman, D. R. and Macpherson, A. J. 2012. Interactions between the microbiota and the immune system. Science 336:1268.
6. Sonnenberg, G. F. and Artis, D. 2012. Innate lymphoid cell interactions with microbiota: implications for intestinal health and disease. Immunity 37:601.
7. Kabat, A. M., Srinivasan, N. and Maloy, K. J. 2014. Modulation of immune development and function by intestinal microbiota. Trends Immunol. 35:507.
8. Brestoff, J. R. and Artis, D. 2013. Commensal bacteria at the interface of host metabolism and the immune system. Nat. Immunol. 14:676.
9. Sommer, F. and Bäckhed, F. 2013. The gut microbiota-masters of host development and physiology. Nat. Rev. Microbiol. 11:227.
10. Garrett, W. S. 2015. Cancer and the microbiota. Science 348:80.
11. Zitvogel, L., Galluzzi, L., Viaud, S. et al. 2015. Cancer and the gut microbiota: an unexpected link. Sci. Transl. Med. 7:271ps1.
12. Artis, D. and Spits, H. 2015. The biology of innate lymphoid cells. Nature 517:293.
13. McKenzie, A. N., Spits, H. and Eberl, G. 2014. Innate lymphoid cells in inflammation and immunity. Immunity 41:366.
14. Sonnenberg, G. F. 2014. Regulation of intestinal health and disease by innate lymphoid cells. Int. Immunol. 26:501.
15. Hepworth, M. R. and Sonnenberg, G. F. 2014. Regulation of the adaptive immune system by innate lymphoid cells. Curr. Opin. Immunol. 27:75.
16. Vonarbourg, C., Mortha, A., Bui, V. L. et al. 2010. Regulated expression of nuclear receptor RORγt confers distinct functional fates to NK cell receptor-expressing RORγt(+) innate lymphocytes. Immunity 33:736.
17. Tian, Z., van Velkinburgh, J.C., Wu, Y. and Ni, B. 2015. Innate lymphoid cells involve in tumorigenesis. Int. J. Cancer. doi:10.1002/ijc.29443.
18. Kirchberger, S., Royston, D. J., Boulard, O. et al. 2013. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J. Exp. Med. 210:917.
19. + mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22. J. Exp. Med. 211:1571.
20. Takayama, T., Kamada, N., Chinen, H. et al. 2010. Imbalance of NKp44(+)NKp46(-) and NKp44(-)NKp46(+) natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology 139:882.
21. Ciccia, F., Accardo-Palumbo, A., Alessandro, R. et al. 2012. Interleukin-22 and interleukin-22-producing NKp44+ natural killer cells in subclinical gut inflammation in ankylosing spondylitis. Arthritis Rheum. 64:1869.
22. Geremia, A., Arancibia-Cárcamo, C. V., Fleming, M. P. et al. 2011. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J. Exp. Med. 208:1127.
23. Bernink, J. H., Peters, C. P., Munneke, M. et al. 2013. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat. Immunol. 14:221.
24. Chan, I. H., Jain, R., Tessmer, M. S. et al. 2014. Interleukin-23 is sufficient to induce rapid de novo gut tumorigenesis, independent of carcinogens, through activation of innate lymphoid cells. Mucosal Immunol. 7:842.
25. Hepworth, M. R., Monticelli, L. A., Fung, T. C. et al. 2013. Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria. Nature 498:113.
26. + T cells. Science 348:1031.
27. Fuchs, A., Vermi, W., Lee, J. S. et al. 2013. Intraepithelial type 1 innate lymphoid cells are a unique subset of IL-12-and IL-15-responsive IFN-γ-producing cells. Immunity 38:769.
28. Bernink, J. H., Krabbendam, L., Germar, K. et al. 2015. Interleukin-12 and-23 Control Plasticity of CD127(+) Group 1 and Group 3 Innate Lymphoid Cells in the Intestinal Lamina Propria. Immunity 43:146.
29. Reedy, J. 1975. Galen on cancer and related diseases. Clio Med. 10:227.
30. Trinchieri, G. 2012. Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu. Rev. Immunol. 30:677.
31. Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C. and Flavell, R. A. 2013. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat. Rev. Cancer 13:759.
32. de Martel, C., Ferlay, J., Franceschi, S. et al. 2012. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13:607.
33. Coley, W. B. 1893. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105:487.
34. Schwabe, R. F. and Jobin, C. 2013. The microbiome and cancer. Nat. Rev. Cancer 13:800.
35. Reddy, B. S., Narisawa, T., Maronpot, R., Weisburger, J. H. and Wynder, E. L. 1975. Animal models for the study of dietary factors and cancer of the large bowel. Cancer Res. 35(11 Pt. 2):3421.
36. Uronis, J. M., Mühlbauer, M., Herfarth, H. H., Rubinas, T. C., Jones, G. S. and Jobin, C. 2009. Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 4:e6026.
37. Vannucci, L., Stepankova, R., Kozakova, H., Fiserova, A., Rossmann, P. and Tlaskalova-Hogenova, H. 2008. Colorectal carcinogenesis in germ-free and conventionally reared rats: different intestinal environments affect the systemic immunity. Int. J. Oncol. 32:609.
38. Yang, L. and Pei, Z. 2006. Bacteria, inflammation, and colon cancer. World J. Gastroenterol. 12:6741.
39. Dove, W. F., Clipson, L., Gould, K. A. et al. 1997. Intestinal neoplasia in the ApcMin mouse: independence from the microbial and natural killer (beige locus) status. Cancer Res. 57:812.
40. Sacksteder, M. R. 1976. Occurrence of spontaneous tumors in the germfree F344 rat. J. Natl Cancer Inst. 57:1371.
41. Schreiber, H., Nettesheim, P., Lijinsky, W., Richter, C. B. and Walburg, H. E. Jr. 1972. Induction of lung cancer in germfree, specific-pathogen-free, and infected rats by N-nitrosoheptamethyleneimine: enhancement by respiratory infection. J. Natl Cancer Inst. 49:1107.
42. Reddy, B. S. and Watanabe, K. 1978. Effect of intestinal microflora on 2, 2'-dimethyl-4-aminobiphenyl-induced carcinogenesis in F344 rats. J. Natl Cancer Inst. 61:1269.
43. Laqueur, G. L., Matsumoto, H. and Yamamoto, R. S. 1981. Comparison of the carcinogenicity of methylazoxymethanol-beta-D-glucosiduronic acid in conventional and germfree Sprague-Dawley rats. J. Natl Cancer Inst. 67:1053.
44. Lofgren, J. L., Whary, M. T., Ge, Z. et al. 2011. Lack of commensal flora in Helicobacter pylori-infected INS-GAS mice reduces gastritis and delays intraepithelial neoplasia. Gastroenterology 140:210.
45. Li, Y., Kundu, P., Seow, S. W. et al. 2012. Gut microbiota accelerate tumor growth via c-jun and STAT3 phosphorylation in APCMin/+ mice. Carcinogenesis 33:1231.
46. Dapito, D. H., Mencin, A., Gwak, G. Y. et al. 2012. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21:504.
47. Rakoff-Nahoum, S. and Medzhitov, R. 2009. Toll-like receptors and cancer. Nat. Rev. Cancer 9:57.
48. Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K. and Knight, R. 2012. Diversity, stability and resilience of the human gut microbiota. Nature 489:220.
49. Garrett, W. S., Punit, S., Gallini, C. A. et al. 2009. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 16:208.
50. Couturier-Maillard, A., Secher, T., Rehman, A. et al. 2013. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J. Clin. Invest. 123:700.
51. Hu, B., Elinav, E., Huber, S. et al. 2013. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc. Natl Acad. Sci. USA 110:9862.
52. Elinav, E., Strowig, T., Kau, A. L. et al. 2011. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145:745.
53. Yoshimoto, S., Loo, T. M., Atarashi, K. et al. 2013. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499:97.
54. Rutkowski, M. R., Stephen, T. L., Svoronos, N. et al. 2015. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27:27.
55. Gagliani, N., Hu, B., Huber, S., Elinav, E. and Flavell, R. A. 2014. The fire within: microbes inflame tumors. Cell 157:776.
56. Dejea, C. M., Wick, E. C., Hechenbleikner, E. M. et al. 2014. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc. Natl Acad. Sci. USA 111:18321.
57. Arthur, J. C., Perez-Chanona, E., Mühlbauer, M. et al. 2012. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338:120.
58. Arthur, J. C., Gharaibeh, R. Z., Mühlbauer, M. et al. 2014. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat. Commun. 5:4724.
59. Kostic, A. D., Chun, E., Robertson, L. et al. 2013. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14:207.
60. Gur, C., Ibrahim, Y., Isaacson, B. et al. 2015. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42:344.
61. Viaud, S., Saccheri, F., Mignot, G. et al. 2013. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342:971.
62. Iida, N., Dzutsev, A., Stewart, C. A. et al. 2013. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342:967.
63. Dzutsev, A., Goldszmid, R. S., Viaud, S., Zitvogel, L. and Trinchieri, G. 2015. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur. J. Immunol. 45:17.
64. Kroemer, G., Galluzzi, L., Kepp, O. and Zitvogel, L. 2013. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31:51.
65. Spits, H. and Di Santo, J. P. 2011. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 12:21.
66. Tait Wojno, E. D. and Artis, D. 2012. Innate lymphoid cells: balancing immunity, inflammation, and tissue repair in the intestine. Cell Host Microbe 12:445.
67. Eberl, G., Colonna, M., Di Santo, J. P. and McKenzie, A. N. 2015. Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology. Science 348:aaa6566.
68. Spits, H., Artis, D., Colonna, M. et al. 2013. Innate lymphoid cells-a proposal for uniform nomenclature. Nat. Rev. Immunol. 13:145.
69. Robinette, M. L., Fuchs, A., Cortez, V. S. et al.; Immunological Genome Consortium. 2015. Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets. Nat. Immunol. 16:306.
70. Sonnenberg, G. F. and Artis, D. 2015. Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat. Med. 21:698.
71. Klose, C. S., Kiss, E. A., Schwierzeck, V. et al. 2013. A T-bet gradient controls the fate and function of CCR6-RORγt+ innate lymphoid cells. Nature 494:261.
72. Hernández, P. P., Mahlakõiv, T., Yang, I. et al. 2015. Interferon-λ and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. Nat. Immunol. 16:698.
73. Cella, M., Fuchs, A., Vermi, W. et al. 2009. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 457:722.
74. Cella, M., Otero, K. and Colonna, M. 2010. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity. Proc. Natl Acad. Sci. USA 107:10961.
75. Cupedo, T., Crellin, N. K., Papazian, N. et al. 2009. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells. Nat. Immunol. 10:66.
76. Luci, C., Reynders, A., Ivanov, I. I. et al. 2009. Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat. Immunol. 10:75.
77. Reynders, A., Yessaad, N., Vu Manh, T. P. et al. 2011. Identity, regulation and in vivo function of gut NKp46+RORγt+ and NKp46+RORγt-lymphoid cells. EMBO J. 30:2934.
78. Sonnenberg, G. F., Fouser, L. A. and Artis, D. 2011. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat. Immunol. 12:383.
79. Dudakov, J. A., Hanash, A. M. and van den Brink, M. R. 2015. Interleukin-22: immunobiology and pathology. Annu. Rev. Immunol. 33:747.
80. Vaishnava, S., Yamamoto, M., Severson, K. M. et al. 2011. The antibacterial lectin RegIIIgamma promotes the spatial segregation of microbiota and host in the intestine. Science 334:255.
81. Wolk, K., Kunz, S., Witte, E., Friedrich, M., Asadullah, K. and Sabat, R. 2004. IL-22 increases the innate immunity of tissues. Immunity 21:241.
82. Liang, S. C., Tan, X. Y., Luxenberg, D. P. et al. 2006. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J. Exp. Med. 203:2271.
83. Wolk, K., Witte, E., Wallace, E. et al. 2006. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur. J. Immunol. 36:1309.
84. Boniface, K., Bernard, F. X., Garcia, M., Gurney, A. L., Lecron, J. C. and Morel, F. 2005. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J. Immunol. 174:3695.
85. Zheng, Y., Valdez, P. A., Danilenko, D. M. et al. 2008. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat. Med. 14:282.
86. Aujla, S. J., Chan, Y. R., Zheng, M. et al. 2008. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nat. Med. 14:275.
87. Sonnenberg, G. F., Monticelli, L. A., Elloso, M. M., Fouser, L. A. and Artis, D. 2011. CD4(+) lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 34:122.
88. Satoh-Takayama, N., Vosshenrich, C. A., Lesjean-Pottier, S. et al. 2008. Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense. Immunity 29:958.
89. Sonnenberg, G. F., Nair, M. G., Kirn, T. J., Zaph, C., Fouser, L. A. and Artis, D. 2010. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J. Exp. Med. 207:1293.
90. Sugimoto, K., Ogawa, A., Mizoguchi, E. et al. 2008. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest. 118:534.
91. Pickard, J. M., Maurice, C. F., Kinnebrew, M. A. et al. 2014. Rapid fucosylation of intestinal epithelium sustains host-commensal symbiosis in sickness. Nature 514:638.
92. Goto, Y., Obata, T., Kunisawa, J. et al. 2014. Innate lymphoid cells regulate intestinal epithelial cell glycosylation. Science 345:1254009.
93. Pham, T. A., Clare, S., Goulding, D. et al.; Sanger Mouse Genetics Project. 2014. Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen. Cell Host Microbe 16:504.
94. Eken, A., Singh, A. K., Treuting, P. M. and Oukka, M. 2014. IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism. Mucosal Immunol. 7:143.
95. Buonocore, S., Ahern, P. P., Uhlig, H. H. et al. 2010. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 464:1371.
96. Sonnenberg, G. F., Monticelli, L. A., Alenghat, T. et al. 2012. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science 336:1321.
97. Qiu, J., Guo, X., Chen, Z. M. et al. 2013. Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora. Immunity 39:386.
98. Goto, Y., Panea, C., Nakato, G. et al. 2014. Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation. Immunity 40:594.
99. van de Pavert, S. A. and Mebius, R. E. 2010. New insights into the development of lymphoid tissues. Nat. Rev. Immunol. 10:664.
100. Randall, T. D. and Mebius, R. E. 2014. The development and function of mucosal lymphoid tissues: a balancing act with micro-organisms. Mucosal Immunol. 7:455.
101. Kruglov, A. A., Grivennikov, S. I., Kuprash, D. V. et al. 2013. Nonredundant function of soluble LTa3 produced by innate lymphoid cells in intestinal homeostasis. Science 342:1243.
102. Magri, G. and Cerutti, A. 2015. Role of group 3 innate lymphoid cells in antibody production. Curr. Opin. Immunol. 33:36.
103. Mortha, A., Chudnovskiy, A., Hashimoto, D. et al. 2014. Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science 343:1249288.
104. Kim, M. Y., Anderson, G., White, A. et al. 2005. OX40 ligand and CD30 ligand are expressed on adult but not neonatal CD4+CD3-inducer cells: evidence that IL-7 signals regulate CD30 ligand but not OX40 ligand expression. J. Immunol. 174:6686.
105. - OX40Lhigh cells express IL-22 and display an LTi phenotype in human secondary lymphoid tissues. Eur. J. Immunol. 41:1563.
106. Withers, D. R., Gaspal, F. M., Mackley, E. C. et al. 2012. Cutting edge: lymphoid tissue inducer cells maintain memory CD4 T cells within secondary lymphoid tissue. J. Immunol. 189:2094.
107. Magri, G., Miyajima, M., Bascones, S. et al. 2014. Innate lymphoid cells integrate stromal and immunological signals to enhance antibody production by splenic marginal zone B cells. Nat. Immunol. 15:354.
108. + ILCs creates a unique microenvironment within mucosal draining lymph nodes. Nat. Commun. 6:5862.
109. Shields, J. D., Kourtis, I. C., Tomei, A. A., Roberts, J. M. and Swartz, M. A. 2010. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328:749.
110. Eisenring, M., vom Berg, J., Kristiansen, G., Saller, E. and Becher, B. 2010. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat. Immunol. 11:1030.
111. Schmutz, S., Bosco, N., Chappaz, S. et al. 2009. Cutting edge: IL-7 regulates the peripheral pool of adult ROR gamma+ lymphoid tissue inducer cells. J. Immunol. 183:2217.
112. Meier, D., Bornmann, C., Chappaz, S. et al. 2007. Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells. Immunity 26:643.
113. Cupedo, T., Jansen, W., Kraal, G. and Mebius, R. E. 2004. Induction of secondary and tertiary lymphoid structures in the skin. Immunity 21:655.
114. Schrama, D., Voigt, H., Eggert, A. O. et al. 2008. Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue. Cancer Immunol. Immunother. 57:85.
115. Schrama, D., Thorstraten, P., Fischer, W. H. et al. 2001. Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 14:111.
116. Yu, P., Lee, Y., Liu, W. et al. 2004. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5:141.
117. Peske, J. D., Thompson, E. D., Gemta, L., Baylis, R. A., Fu, Y. X. and Engelhard, V. H. 2015. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat. Commun. 6:7114.
118. Dieu-Nosjean, M. C., Goc, J., Giraldo, N. A., Sautès-Fridman, C. and Fridman, W. H. 2014. Tertiary lymphoid structures in cancer and beyond. Trends Immunol. 35:571.
119. Pitzalis, C., Jones, G. W., Bombardieri, M. and Jones, S. A. 2014. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14:447.
120. Goc, J., Germain, C., Vo-Bourgais, T. K. et al. 2014. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 74:705.
121. Germain, C., Gnjatic, S., Tamzalit, F. et al. 2014. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 189:832.
122. + follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123:2873.
123. Di Caro, G., Bergomas, F., Grizzi, F. et al. 2014. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin. Cancer Res. 20:2147.
124. Lochner, M., Ohnmacht, C., Presley, L. et al. 2011. Microbiotainduced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORgamma t and LTi cells. J. Exp. Med. 208:125.
125. Lim, C. and Savan, R. 2014. The role of the IL-22/IL-22R1 axis in cancer. Cytokine Growth Factor Rev. 25:257.
126. Huber, S., Gagliani, N., Zenewicz, L. A. et al. 2012. IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature 491:259.
127. Fridman, W. H., Pagès, F., Sautès-Fridman, C. and Galon, J. 2012. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12:298.
128. Xu, X., Tang, Y., Guo, S. et al. 2014. Increased intratumoral interleukin 22 levels and frequencies of interleukin 22-producing CD4+ T cells correlate with pancreatic cancer progression. Pancreas 43:470.
129. Ye, Z. J., Zhou, Q., Yin, W. et al. 2012. Interleukin 22-producing CD4+ T cells in malignant pleural effusion. Cancer Lett. 326:23.
130. Liu, T., Peng, L., Yu, P. et al. 2012. Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer. J. Clin. Immunol. 32:1332.
131. Zhuang, Y., Peng, L. S., Zhao, Y. L. et al. 2012. Increased intratumoral IL-22-producing CD4(+) T cells and Th22 cells correlate with gastric cancer progression and predict poor patient survival. Cancer Immunol. Immunother. 61:1965.
132. Huang, Y. H., Cao, Y. F., Jiang, Z. Y., Zhang, S. and Gao, F. 2015. Th22 cell accumulation is associated with colorectal cancer development. World J. Gastroenterol. 21:4216.
133. Langowski, J. L., Zhang, X., Wu, L. et al. 2006. IL-23 promotes tumour incidence and growth. Nature 442:461.
134. Grivennikov, S. I., Wang, K., Mucida, D. et al. 2012. Adenomalinked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491:254.
135. Tosolini, M., Kirilovsky, A., Mlecnik, B. et al. 2011. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res. 71:1263.
136. Kryczek, I., Lin, Y., Nagarsheth, N. et al. 2014. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 40:772.
137. Liu, J., Duan, Y., Cheng, X. et al. 2011. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem. Biophys. Res. Commun. 407:348.